Co-Diagnostics Inc. Common Stock (CODX)

About CODX

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic test…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

115

Website

codiagnostics.com/

Fundamentals

1-day range

$1.18$1.29

Market cap

$9.91M

P/E (trailing)

—

P/E (forward)

-1.46

EPS (trailing)

$-29.39

Dividend yield

—

Beta

2.92

Avg. volume

624.6K

Forecasts

1 analyst ratings

Co-Diagnostics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CODX

  Co-Diagnostics Inc. Common Stock

  $1.2

  ▼ 4.76%
  Market cap $9.91MP/E —
  $0.9396$46.5
• SINT

  SiNtx Technologies Inc. Common Stock

  $1.51

  ▼ 1.31%
  Market cap $10.36MP/E —
  $1.4$6.78
• MODD

  Modular Medical Inc. Common Stock

  $3.3

  ▼ 8.73%
  Market cap $10.99MP/E —
• ICU

  SeaStar Medical Holding Corporation Common Stock

  $3.08

  ▼ 0.81%
  Market cap $12.19MP/E —
• NVNO

  enVVeno Medical Corporation Common Stock

  $10.67

  ▼ 5.12%
  Market cap $6.93MP/E —
  $8.67$36.05
• NMTC

  NeuroOne Medical Technologies Corporation Common Stock

  $1.8

  ▼ 9.09%
  Market cap $13.36MP/E —
  $1.42$6.96
• XAIR

  Beyond Air Inc. Common Stock

  $4.58

  ▼ 19.65%
  Market cap $4.93MP/E —
  $4.37$95.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
  Benzinga · 8/28/2026
• Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026
• Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K Estimate
  Benzinga · 8/13/2026

• Richard David Abbott · May 23, 2026 · Option Exercise

  1.9K
• Richard David Abbott · May 23, 2026 · Disposition

  680 @ $5.07
• Richard David Abbott · May 23, 2026 · Grant

  1.9K
• Brian Lee Brown · May 23, 2026 · Option Exercise

  3.8K
• Brian Lee Brown · May 23, 2026 · Disposition

  1.4K @ $5.07
• Brian Lee Brown · May 23, 2026 · Grant

  3.8K
• Eugene Durenard · May 23, 2026 · Option Exercise

  1.7K
• Eugene Durenard · May 23, 2026 · Grant

  1.7K
• Edward L. Murphy · May 23, 2026 · Option Exercise

  1.7K
• Edward L. Murphy · May 23, 2026 · Grant

  1.7K
• Dwight H. Egan · May 23, 2026 · Option Exercise

  4.6K
• Dwight H. Egan · May 23, 2026 · Disposition

  1.6K @ $5.07
• Dwight H. Egan · May 23, 2026 · Grant

  4.6K
• James B. Nelson · May 23, 2026 · Option Exercise

  1.7K
• James B. Nelson · May 23, 2026 · Grant

  1.7K

Institutional Ownership

March 31, 2026

Total shares held

49.2K

Total value held

$91.4K

Institutional holders

12